Elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels have been associated with adverse outcomes in patients hospitalized for sepsis. PCSK9 loss-of-function (LOF) variants area ...

A new case-control genetic study is reassuring in finding no association between a genetic proxy for pharmacologic PCSK9 inhibition and either heart failure or adverse cardiac remodeling in a large ...

How does PCSK9 function and what is the impact of this protein on cardiovascular disease? A research team coordinated by Dr. Nabil G. Seidah, researcher at the IRCM and at Université de Montréal, has ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Please provide your email address to receive an email when new articles are posted on . “PCSK9 inhibition, as modeled via genetic Mendelian randomization methods, has a neutral cognitive profile,” ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert ...

Verve is targeting patients with genetically-driven high cholesterol levels, and they are making a single A-to-G change in the gene for the PCSK9 protein. Verve announced their results yesterday, and ...

NEW ORLEANS, LA—Use of enlicitide 20 mg, an oral PCSK9 inhibitor, significantly cut levels of LDL cholesterol and other atherogenic lipids in a large cohort of high-risk patients, results from the ...

Peter Salgo, MD: Let’s talk about the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. We’ve talked around them. We discussed them. We talked about the research. Now, let’s talk about ...

DALLAS – April 17, 2009 – Researchers at UT Southwestern Medical Center have found that a protein responsible for regulating "bad" cholesterol in the blood works almost exclusively outside cells, ...